Setting

Asia Pacific Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Country: Trend Forecast and Growth Opportunity

Published: 30 Nov 2021 | Report Code: 10248261 | Pages: 116

Asia Pacific biosimilars market will grow by 30.7% annually with a total addressable market cap of $140.4 billion over 2021-2030 owing to the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent expirations of many blockbuster drugs, and better healthcare provisions. Highlighted with 33 tables and 56 figures, this 116-page report “Asia Pacific Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific biosimilars market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19). In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific biosimilars market in every aspect of the classification from perspectives of Product Type, Indication, Manufacturing, End User, and Country. Based on Product Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Recombinant Non-glycosylated Biosimilars o Insulin o Recombinant Human Growth Hormone (rHGH) o Granulocyte Colony Stimulating Factor o Interferon • Recombinant Glycosylated Biosimilars o Monoclonal Antibodies (mAb) o Erythropoietin (EPO) o Follicle Stimulating Hormone • Recombinant Peptides and Others o Tumor Necrosis Factor (TNF)-Inhibitor o Parathyroid Hormone o Enzymes, Immunomodulators, GnRH Analogs and Others Based on Indication, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Cancer • Autoimmune Disease • Blood Disorder • Diabetes • Growth Hormone Deficiency • Infectious Diseases • Other Indications Based on Manufacturing, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Contract Manufacturing • Inhouse Manufacturing Based on End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Hospitals and Clinics • Research Institutes • Other End Users Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2019-2030. The breakdown of key national markets by Product Type, Indication, and End User over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): AMEGA Biotech S.A. Apotex Inc. Biocon Ltd Biogen Inc. Boehringer Ingelheim Celltrion, Inc. Dr. Reddy’s Laboratories Ltd. Eli Lilly and Company Intas Pharmaceuticals Ltd. LG Chem, Ltd. Merck and Co. Inc. Mylan N.V. Pfizer Inc. Samsung Biologics Co., Ltd. Sandoz International GmbH STADA Arzneimittel AG Teva Pharmaceutical Industries Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents:
1 Introduction	7
1.1 Industry Definition and Research Scope	7
1.1.1 Industry Definition	7
1.1.2 Research Scope	8
1.2 Research Methodology	11
1.2.1 Overview of Market Research Methodology	11
1.2.2 Market Assumption	12
1.2.3 Secondary Data	12
1.2.4 Primary Data	12
1.2.5 Data Filtration and Model Design	13
1.2.6 Market Size/Share Estimation	14
1.2.7 Research Limitations	15
1.3 Executive Summary	16
2 Market Overview and Dynamics	19
2.1 Market Size and Forecast	19
2.1.1 Impact of COVID-19 on World Economy	22
2.1.2 Impact of COVID-19 on the Market	25
2.2 Major Growth Drivers	27
2.3 Market Restraints and Challenges	32
2.4 Emerging Opportunities and Market Trends	35
2.5 Porter’s Fiver Forces Analysis	39
3 Segmentation of Asia Pacific Market by Product Type	43
3.1 Market Overview by Product Type	43
3.2 Recombinant Non-glycosylated Biosimilars	45
3.2.1 Insulin	47
3.2.2 Recombinant Human Growth Hormone (rHGH)	48
3.2.3 Granulocyte Colony Stimulating Factor	49
3.2.4 Interferon	50
3.3 Recombinant Glycosylated Biosimilars	51
3.3.1 Monoclonal Antibodies (mAb)	52
3.3.2 Erythropoietin (EPO)	53
3.3.3 Follicle Stimulating Hormone	54
3.4 Recombinant Peptides and Others	55
3.4.1 Tumor Necrosis Factor (TNF)-Inhibitor	56
3.4.2 Parathyroid Hormone	57
3.4.3 Enzymes, Immunomodulators, GnRH Analogs and Others	58
4 Segmentation of Asia Pacific Market by Indication	59
4.1 Market Overview by Indication	59
4.2 Cancer	61
4.3 Autoimmune Disease	62
4.4 Blood Disorder	63
4.5 Diabetes	64
4.6 Growth Hormone Deficiency	65
4.7 Infectious Diseases	66
4.8 Other Indications	67
5 Segmentation of Asia Pacific Market by Manufacturing	68
5.1 Market Overview by Manufacturing	68
5.2 Contract Manufacturing	70
5.3 Inhouse Manufacturing	71
6 Segmentation of Asia Pacific Market by End User	72
6.1 Market Overview by End User	72
6.2 Hospitals and Clinics	74
6.3 Research Institutes	75
6.4 Other End Users	76
7 Asia-Pacific Market 2019-2030 by Country	77
7.1 Overview of Asia-Pacific Market	77
7.2 Japan	80
7.3 China	83
7.4 Australia	85
7.5 India	87
7.6 South Korea	89
7.7 Rest of APAC Region	91
8 Competitive Landscape	93
8.1 Overview of Key Vendors	93
8.2 New Product Launch, Partnership, Investment, and M&A	97
8.3 Company Profiles	98
AMEGA Biotech S.A.	98
Apotex Inc.	100
Biocon Ltd	101
Biogen Inc.	102
Boehringer Ingelheim	103
Celltrion, Inc.	104
Dr. Reddy’s Laboratories Ltd.	105
Eli Lilly and Company	106
Intas Pharmaceuticals Ltd.	107
LG Chem, Ltd.	108
Merck and Co. Inc.	109
Mylan N.V.	110
Pfizer Inc.	111
Samsung Biologics Co., Ltd.	112
Sandoz International GmbH	113
STADA Arzneimittel AG	114
Teva Pharmaceutical Industries Ltd.	115
RELATED REPORTS	116
List Of Tables:

Table 1.  Snapshot of Asia Pacific Biosimilars Market in Balanced Perspective, 2019-2030	17
Table 2. Growth Rate of World GDP, 2020-2022	23
Table 3. World Health Spending by Region, $ bn, 2013-2020	31
Table 4.  Main Product Trends and Market Opportunities in Asia Pacific Biosimilars Market	35
Table 5. Asia Pacific Biosimilars Market by Product Type, 2019-2030, $ mn	43
Table 6. Asia Pacific Biosimilars Market: Recombinant Non-glycosylated Biosimilars by Product, 2019-2030, $ mn	46
Table 7. Asia Pacific Biosimilars Market: Recombinant Glycosylated Biosimilars by Product, 2019-2030, $ mn	51
Table 8. Asia Pacific Biosimilars Market: Recombinant Peptides and Others by Product, 2019-2030, $ mn	55
Table 9. Asia Pacific Biosimilars Market by Indication, 2019-2030, $ mn	59
Table 10. Asia Pacific Biosimilars Market by Manufacturing, 2019-2030, $ mn	68
Table 11. Asia Pacific Biosimilars Market by End User, 2019-2030, $ mn	72
Table 12. APAC Biosimilars Market by Country, 2019-2030, $ mn	78
Table 13. Japan Biosimilars Market by Product Type, 2019-2030, $ mn	82
Table 14. Japan Biosimilars Market by Indication, 2019-2030, $ mn	82
Table 15. Japan Biosimilars Market by End User, 2019-2030, $ mn	82
Table 16. China Biosimilars Market by Product Type, 2019-2030, $ mn	84
Table 17. China Biosimilars Market by Indication, 2019-2030, $ mn	84
Table 18. China Biosimilars Market by End User, 2019-2030, $ mn	84
Table 19. Australia Biosimilars Market by Product Type, 2019-2030, $ mn	86
Table 20. Australia Biosimilars Market by Indication, 2019-2030, $ mn	86
Table 21. Australia Biosimilars Market by End User, 2019-2030, $ mn	86
Table 22. India Biosimilars Market by Product Type, 2019-2030, $ mn	88
Table 23. India Biosimilars Market by Indication, 2019-2030, $ mn	88
Table 24. India Biosimilars Market by End User, 2019-2030, $ mn	88
Table 25. South Korea Biosimilars Market by Product Type, 2019-2030, $ mn	90
Table 26. South Korea Biosimilars Market by Indication, 2019-2030, $ mn	90
Table 27. South Korea Biosimilars Market by End User, 2019-2030, $ mn	90
Table 28. Biosimilars Market in Rest of APAC by Country/Region, 2019-2030, $ mn	92
Table 29. Breakdown of World Market by Key Vendor, 2020, %	95
Table 30. AMEGA Biotech S.A.: Company Snapshot	98
Table 31. AMEGA Biotech S.A.: Business Segmentation	98
Table 32. AMEGA Biotech S.A.: Product Portfolio	99
Table 33. AMEGA Biotech S.A.: Revenue, 2018-2020, $ mn	99
List Of Figures:

Figure 1. Research Method Flow Chart	11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation	14
Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030	16
Figure 4. Asia Pacific Biosimilars Market, 2019-2030, $ mn	19
Figure 5. EMA and FDA Biosimilar Approvals, 2015 - 2019	20
Figure 6. EMA-approved Biosimilars Distribution by Reference Product and Therapeutic Area	20
Figure 7. FDA-approved Biosimilars Distribution by Reference Product and Therapeutic Area	21
Figure 8. Impact of COVID-19 on Business	25
Figure 9. Primary Drivers and Impact Factors of Asia Pacific Biosimilars Market	27
Figure 10.  Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million	30
Figure 11. World Population 65 and Over, % of Total Population, 1950-2060	30
Figure 12. Primary Restraints and Impact Factors of Asia Pacific Biosimilars Market	32
Figure 13. Investment Opportunity Analysis	36
Figure 14. Porter’s Fiver Forces Analysis of Asia Pacific Biosimilars Market	39
Figure 15. Breakdown of Asia Pacific Biosimilars Market by Product Type, 2019-2030, % of Revenue	44
Figure 16. Asia Pacific Addressable Market Cap in 2021-2030 by Product Type, Value ($ mn) and Share (%)	44
Figure 17. Asia Pacific Biosimilars Market by Product Type: Recombinant Non-glycosylated Biosimilars, 2019-2030, $ mn	45
Figure 18. Asia Pacific Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Insulin, 2019-2030, $ mn	47
Figure 19. Asia Pacific Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Recombinant Human Growth Hormone (rHGH), 2019-2030, $ mn	48
Figure 20. Asia Pacific Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Granulocyte Colony Stimulating Factor, 2019-2030, $ mn	49
Figure 21. Asia Pacific Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Interferon, 2019-2030, $ mn	50
Figure 22. Asia Pacific Biosimilars Market by Product Type: Recombinant Glycosylated Biosimilars, 2019-2030, $ mn	51
Figure 23. Asia Pacific Biosimilars Market by Recombinant Glycosylated Biosimilars: Monoclonal Antibodies (mAb), 2019-2030, $ mn	52
Figure 24. Asia Pacific Biosimilars Market by Recombinant Glycosylated Biosimilars: Erythropoietin (EPO), 2019-2030, $ mn	53
Figure 25. Asia Pacific Biosimilars Market by Recombinant Glycosylated Biosimilars: Follicle Stimulating Hormone, 2019-2030, $ mn	54
Figure 26. Asia Pacific Biosimilars Market by Product Type: Recombinant Peptides and Others, 2019-2030, $ mn	55
Figure 27. Asia Pacific Biosimilars Market by Recombinant Peptides and Others: Tumor Necrosis Factor (TNF)-Inhibitor, 2019-2030, $ mn	56
Figure 28. Asia Pacific Biosimilars Market by Recombinant Peptides and Others: Parathyroid Hormone, 2019-2030, $ mn	57
Figure 29. Asia Pacific Biosimilars Market by Recombinant Peptides and Others: Enzymes, Immunomodulators, GnRH Analogs and Others, 2019-2030, $ mn	58
Figure 30. Breakdown of Asia Pacific Biosimilars Market by Indication, 2019-2030, % of Sales Revenue	60
Figure 31. Asia Pacific Addressable Market Cap in 2021-2030 by Indication, Value ($ mn) and Share (%)	60
Figure 32. Asia Pacific Biosimilars Market by Indication: Cancer, 2019-2030, $ mn	61
Figure 33. Asia Pacific Biosimilars Market by Indication: Autoimmune Disease, 2019-2030, $ mn	62
Figure 34. Asia Pacific Biosimilars Market by Indication: Blood Disorder, 2019-2030, $ mn	63
Figure 35. Asia Pacific Biosimilars Market by Indication: Diabetes, 2019-2030, $ mn	64
Figure 36. Asia Pacific Biosimilars Market by Indication: Growth Hormone Deficiency, 2019-2030, $ mn	65
Figure 37. Asia Pacific Biosimilars Market by Indication: Infectious Diseases, 2019-2030, $ mn	66
Figure 38. Asia Pacific Biosimilars Market by Indication: Other Indications, 2019-2030, $ mn	67
Figure 39. Breakdown of Asia Pacific Biosimilars Market by Manufacturing, 2019-2030, % of Sales Revenue	69
Figure 40. Asia Pacific Addressable Market Cap in 2021-2030 by Manufacturing, Value ($ mn) and Share (%)	69
Figure 41. Asia Pacific Biosimilars Market by Manufacturing: Contract Manufacturing, 2019-2030, $ mn	70
Figure 42. Asia Pacific Biosimilars Market by Manufacturing: Inhouse Manufacturing, 2019-2030, $ mn	71
Figure 43. Breakdown of Asia Pacific Biosimilars Market by End User, 2019-2030, % of Revenue	73
Figure 44. Asia Pacific Addressable Market Cap in 2021-2030 by End User, Value ($ mn) and Share (%)	73
Figure 45. Asia Pacific Biosimilars Market by End User: Hospitals and Clinics, 2019-2030, $ mn	74
Figure 46. Asia Pacific Biosimilars Market by End User: Research Institutes, 2019-2030, $ mn	75
Figure 47. Asia Pacific Biosimilars Market by End User: Other End Users, 2019-2030, $ mn	76
Figure 48. Breakdown of APAC Biosimilars Market by Country, 2019 and 2030, % of Revenue	78
Figure 49. Contribution to APAC 2021-2030 Cumulative Market by Country, Value ($ mn) and Share (%)	79
Figure 50.  Biosimilars Market in Japan, 2019-2030, $ mn	81
Figure 51.  Biosimilars Market in China, 2019-2030, $ mn	83
Figure 52.  Biosimilars Market in Australia, 2019-2030, $ mn	85
Figure 53.  Biosimilars Market in India, 2019-2030, $ mn	87
Figure 54.  Biosimilars Market in South Korea, 2019-2030, $ mn	89
Figure 55.  Biosimilars Market in Rest of APAC, 2019-2030, $ mn	91
Figure 56. Growth Stage of Asia Pacific Biosimilars Industry over the Forecast Period	93
Key Players (this may not be a complete list and extra companies can be added upon request): 
AMEGA Biotech S.A.
Apotex Inc.
Biocon Ltd
Biogen Inc.
Boehringer Ingelheim
Celltrion, Inc.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
Intas Pharmaceuticals Ltd.
LG Chem, Ltd.
Merck and Co. Inc.
Mylan N.V.
Pfizer Inc.
Samsung Biologics Co., Ltd.
Sandoz International GmbH
STADA Arzneimittel AG
Teva Pharmaceutical Industries Ltd. 
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)